ClinicalTrials.gg
CompletedNCT00506025Updated Dec 18, 2017Results posted

Effectiveness of Cranberry Ingestion on Bacterial Adhesion: An Adjunct Study

An interventional study of Cranberry Juice and De-Activated Cranberry juice in Asymptomatic Bacteriuria, sponsored by University of California, Irvine. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-18.

Sponsored by University of California, Irvine · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
51
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

This study is to help determine if drinking cranberry juice can decrease risk for asymptomatic bacteriuria (ASB). ASB occurs when there are bacteria in the urine without any symptoms. It will also see if there is a difference in this effect between pregnant and non-pregnant women.This research project is also designed to see what happens to bacterial binding to the lining of the bladder after drinking cranberry juice when special problems occur with pregnancy such as diabetes (a sugar metabolism problem) or ASB is already occurring.

Read the detailed description

This study is an adjunct to a proposal the premise of which is daily cranberry ingestion during pregnancy may be an effective preventative approach to development of asymptomatic bacteriuria (ASB), a condition which predisposes to both preterm birth and upper urinary tract infection. We proposed to NCCAM a pilot randomized, controlled trial (RCT) in which pregnant women beyond 12 weeks' gestational age will be assigned to one of three schedules for cranberry ingestion: Group A will consume cranberry juice twice a day with breakfast and dinner; Group B will consume cranberry juice at breakfast followed by placebo at dinner; and Group C will consume placebo with meals. Both the cranberry juice and placebo will be of scientific grade, provided by an NIH-contractor. Both are well-characterized, presenting a low-carbohydrate load and low-calorie content per dose (40 cal per 8 oz. dose). Our intent is to 1) generate data comparing the frequency of asymptomatic bacteriuria in pregnant women consuming cranberry juice daily versus placebo, and to 2) create the infrastructure to complete this pilot study and to gather sufficient data to support an R01 for a larger, multi-center RCT focused on the prevention of ASB in pregnancy with daily cranberry juice ingestion.

The reviewers of our proposal enumerated specific weaknesses including 1) a need to evaluate urine from cranberry treated patients, and 2) consideration of bacterial virulence/adherence. The additional variable of gestational diabetes also received comment from the reviewers, and we acknowledge that predisposition in the Hispanic population to this obstetrical complication could impact results. A constituent of cranberries is fructose, which has been implicated in the inhibition of E. coli with type 1 fimbriae (mannose-sensitive) (2). We hypothesize that the glucosuria associated with diabetes in pregnancy may influence the effectiveness of cranberry to prevent asymptomatic bacteriuria.

We must address these weaknesses to strengthen chances for continued funding and competitive renewal.

We have made inquiries with other researchers, and have discovered no direct urine or serum assays by which to measure cranberry metabolites. We understand that there is an R21 proposal under consideration to develop a urinary assay for this purpose under the same RFA. Amy Howell, PhD, of the Marucci Center for Blueberry/Cranberry Research of Rutgers University, one of the field's foremost researchers in this field, and others have indirectly assayed compliance to cranberry by evaluating adherence of piliated E. coli strains before and after cranberry exposure (1). In response to the recent call for proposals for faculty research from the UCI Committee on Research, I proposed this pilot study in collaboration with Dr. Howell.

In this proposal, we will collect the urine from various participants in the R21 trial so as to characterize the effect of cranberry juice ingestion on bacterial adherence. We will ask women to collect their urine for a four-hour time period including first-morning void. The urine samples will be sent to Dr. Howell's laboratory at Rutgers University for analysis. We will collect urine from pregnant women who are assigned to cranberry and to placebo, and from those women who develop bacteriuria following cranberry and following placebo ingestion. We also plan to identify a group of reproductive age, healthy, and non-pregnant women to ingest the active cranberry product or placebo for three days, and on the third day, collect a four-hour timed sample in the same manner as the pregnant women in our control group.

02

Conditions studied

  • Asymptomatic Bacteriuria

Browse trials for

Keywords

  • Pregnancy
  • Cranberry
  • Asymptomatic Bacteruria
03

In context

Bacteriuria

51 studies on the registry are indexed under Bacteriuria; 3 are open to participants now.

This study's enrollment of 51 is below the median of 100 across 37 interventional studies indexed under Bacteriuria.

Browse Bacteriuria studies →

Lead sponsor

University of California, Irvine is the lead sponsor of 476 studies on the registry; 98 are open to participants now.

Of its 41 completed or terminated interventional studies of FDA-regulated products, 30 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Intrauterine pregnancy
  • Documented fetal viability (either by fetal heart tones present by Doppler auscultation, or by ultrasonic visualization of cardiac motion
  • Estimated gestational age by last menstrual period and/or by ultrasonographic fetal measurements of 16 weeks or less

Exclusion Criteria:

  • Exclusion criteria will include:
  • Suspected non-viable or ectopic gestation
  • Patient desires pregnancy termination
  • Significant underlying medical complication, such as chronic hypertension, insulin-requiring diabetes, chronic renal failure, cardiac disease, sickle cell disease, etc.
  • Maternal age less than 18 years
  • Patient is currently on or has received within the two weeks prior to enrollment antimicrobial therapy for reasons other than urinary tract infection.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Active comparator
    Cranberry 2xday

    Cranberry juice (C) two times daily, a.m. and p.m.

    Dietary Supplement: Cranberry Juice

  • Active comparator
    Cranberry + Placebo

    De-Activated Cranberry juice in the am, then placebo (P) in the pm

    Dietary Supplement: Cranberry Juice

  • Placebo comparator
    Placebo 2xday

    Placebo in the form of juice two times daily in the a.m. and p.m.

    Dietary Supplement: De-Activated Cranberry juice

Interventions

  • Dietary supplementCranberry Juice

    Low-calorie, Low-carbohydrate content 8 oz dose of Cranberry juice

  • Dietary supplementDe-Activated Cranberry juice

    De-Activated Cranberry juice in the am, then placebo (P) in the pm

06

What researchers measure

Primary outcomes

  1. Antimicrobial Activity of Urine From Pregnant Subjects Following Cranberry Juice Cocktail (CJC)

    The primary outcome measure was the measurement of bacteriuria in study subject urine, defined as having a urine culture with 100,000 or more of a single uropathogen (measured as cfu per ml).

    Time frame: 7 months, from enrollment at 3 months of pregnancy to delivery

07

Results

Posted Jun 8, 2010
Limitations and caveats
Our study methodology could have been improved with a series of timed urine collections such as collections at pre-treatment, 2, 4 and 6 hours after ingestion of the cranberry juice cocktail and placebo to determine time of maximal effect.

Participant flow

Twenty-seven pregnant women who were enrolled were randomly selected for recruitment into this investigation.

Participant flow — Overall Study
MilestoneCranberry 2xdayCranberry + PlaceboPlacebo 2xday
Started1098
Completed1098
Not completed000

Outcome measures

PrimaryAntimicrobial Activity of Urine From Pregnant Subjects Following Cranberry Juice Cocktail (CJC)

The primary outcome measure was the measurement of bacteriuria in study subject urine, defined as having a urine culture with 100,000 or more of a single uropathogen (measured as cfu per ml).

Time frame:
7 months, from enrollment at 3 months of pregnancy to delivery
Reported as:
Median · cfu per ml
Antimicrobial Activity of Urine From Pregnant Subjects Following Cranberry Juice Cocktail (CJC)
cfu per mlCranberry 2xdayCranberry + PlaceboPlacebo 2xday
Antimicrobial Activity of Urine From Pregnant Subjects Following Cranberry Juice Cocktail (CJC)117.5 (11.0 to 310.0)105.0 (41.0 to 385.0)110.0 (3.0 to 200.0)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cranberry 2xday—0/27 (0%)0/27 (0%)
Cranberry + Placebo—0/27 (0%)0/27 (0%)
Placebo 2xday—0/27 (0%)0/27 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cranberry 2xdayCranberry + PlaceboPlacebo 2xdayTotal
<=18 years0000
Between 18 and 65 years109827
>=65 years0000
Age, Continuous
Age, Continuous(years)Cranberry 2xdayCranberry + PlaceboPlacebo 2xdayTotal
Mean29 ± 5.2627 ± 5.2624.5 ± 5.2626.83 ± 5.263
Sex: Female, Male
Sex: Female, Male(Participants)Cranberry 2xdayCranberry + PlaceboPlacebo 2xdayTotal
Female109827
Male0000
Region of Enrollment
Region of Enrollment(participants)Cranberry 2xdayCranberry + PlaceboPlacebo 2xdayTotal
United States109827
08

Study locations

1 site
  • University of California, Irvine Medical Center
    Orange, California 92868, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2010, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2007
First posted
Jul 25, 2007
Start
Aug 2006
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Results first posted
Jun 8, 2010
Last update
Dec 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00506025
Responsible party
Deborah A. Wing (Director, Division of Maternal-Fetal Medicine, Obstetrics & Gynecology, University of California, Irvine School of Medicine, University of California, Irvine) — Principal investigator
First posted
Jul 25, 2007
Start date
Aug 2006
Primary completion
Feb 2008
Completion
Feb 2008
Results posted
Jun 8, 2010
Last update
Dec 18, 2017

Study contacts

Deborah A Wing, MD
principal investigator · University of California, Irvine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cranberry juice

Start the discussion